| Creatine and creatinine metabolism M Wyss, R Kaddurah-Daouk Physiological reviews 80 (3), 1107-1213, 2000 | 3302 | 2000 |
| Metabolomics: a global biochemical approach to drug response and disease R Kaddurah-Daouk, BS Kristal, RM Weinshilboum Annu. Rev. Pharmacol. Toxicol. 48, 653-683, 2008 | 838 | 2008 |
| Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis P Klivenyi, RJ Ferrante, RT Matthews, MB Bogdanov, AM Klein, ... Nature medicine 5 (3), 347-350, 1999 | 822 | 1999 |
| Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease RJ Ferrante, OA Andreassen, BG Jenkins, A Dedeoglu, S Kuemmerle, ... Journal of Neuroscience 20 (12), 4389-4397, 2000 | 656 | 2000 |
| Metabolomics enables precision medicine:“a white paper, community perspective” RD Beger, W Dunn, MA Schmidt, SS Gross, JA Kirwan, M Cascante, ... Metabolomics 12, 1-15, 2016 | 538 | 2016 |
| The metabolomics standards initiative (MSI) O Fiehn, D Robertson, J Griffin, M van der Werf, B Nikolau, N Morrison, ... Metabolomics 3, 175-178, 2007 | 506 | 2007 |
| Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington’s disease RT Matthews, L Yang, BG Jenkins, RJ Ferrante, BR Rosen, ... Journal of Neuroscience 18 (1), 156-163, 1998 | 499 | 1998 |
| Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—an emerging role for gut microbiome S MahmoudianDehkordi, M Arnold, K Nho, S Ahmad, W Jia, G Xie, ... Alzheimer's & Dementia 15 (1), 76-92, 2019 | 483 | 2019 |
| Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics X Han, S Rozen, SH Boyle, C Hellegers, H Cheng, JR Burke, ... PloS one 6 (7), e21643, 2011 | 471 | 2011 |
| Creatine and cyclocreatine attenuate MPTP neurotoxicity RT Matthews, RJ Ferrante, P Klivenyi, L Yang, AM Klein, G Mueller, ... Experimental neurology 157 (1), 142-149, 1999 | 466 | 1999 |
| Metabolic network failures in Alzheimer's disease: A biochemical road map JB Toledo, M Arnold, G Kastenmüller, R Chang, RA Baillie, X Han, ... Alzheimer's & Dementia 13 (9), 965-984, 2017 | 404 | 2017 |
| Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study VR Varma, AM Oommen, S Varma, R Casanova, Y An, RM Andrews, ... PLoS medicine 15 (1), e1002482, 2018 | 390 | 2018 |
| Metabolomics tools for identifying biomarkers for neuropsychiatric diseases MP Quinones, R Kaddurah-Daouk Neurobiology of disease 35 (2), 165-176, 2009 | 340 | 2009 |
| The metabolomics standards initiative Nature biotechnology 25 (8), 846-848, 2007 | 335 | 2007 |
| Metabolomics: a global biochemical approach to the study of central nervous system diseases R Kaddurah-Daouk, K Krishnan Neuropsychopharmacology 34 (1), 173-186, 2009 | 329 | 2009 |
| Metabolomic mapping of atypical antipsychotic effects in schizophrenia R Kaddurah-Daouk, J McEvoy, RA Baillie, D Lee, JK Yao, ... Molecular psychiatry 12 (10), 934-945, 2007 | 309 | 2007 |
| Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities, and plans AJ Saykin, L Shen, X Yao, S Kim, K Nho, SL Risacher, VK Ramanan, ... Alzheimer's & Dementia 11 (7), 792-814, 2015 | 282 | 2015 |
| Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: relationship to neuroimaging and CSF biomarkers K Nho, A Kueider-Paisley, S MahmoudianDehkordi, M Arnold, ... Alzheimer's & Dementia 15 (2), 232-244, 2019 | 246 | 2019 |
| Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review AH Emwas, C Luchinat, P Turano, L Tenori, R Roy, RM Salek, D Ryan, ... Metabolomics 11, 872-894, 2015 | 246 | 2015 |
| Enteric microbiome metabolites correlate with response to simvastatin treatment R Kaddurah-Daouk, RA Baillie, H Zhu, ZB Zeng, MM Wiest, UT Nguyen, ... PLoS One 6 (10), e25482, 2011 | 221 | 2011 |
